CClinicalTrials.gg
CompletedNCT04695912Updated Jan 5, 2021

The Effect of Accelerometer Guided App Feedback on Change in Activity in Patients With Low Back

An interventional study of The SENS motion® sensor in Low Back Pain, Radiculopathy Lumbar and Sciatica, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Apr 2019, registered Dec 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In a cross-over, open-label, randomized, controlled trial, the investigators aim to determine if the daily activity level in patients with LBP can be increased via feedback from an app, connected to a wearable sensor of physical activity.

Read the detailed description

The aim of the study is to determine if a wearable device that measure physical activity and a smartphone application with nudges and feedback increase the physical activity level of patients with low back pain over a 14 days period.

Secondary to determine how many of the patients, that use the smartphone application, and if they perceived the feedback as inspiring.

And to explore, if a potential effect of the device and smartphone application depended on the baseline activity level, gender, diagnoses, age, education level and previous exercise experience.

  1. Is there a difference in average (mean) daily number of active minutes (defined as walking, cycling, running or exercise) over the 14 days intervention period compared to the 14 days control period.
  2. If there is an effect of the device and smartphone application, then determine how many of the patients, that use the smartphone application, and if they perceived the feedback as inspiring.

    To explore, if a potential effect of the device and smartphone application depended on the baseline activity level, gender, diagnoses, age, education level and previous exercise experience.

  3. Is the outcome measures; function measured by sensor, the subjective measurements as pain, stiffness and function, responsive to the intervention compared, to the global scale. 4. Is the patient´s self-evaluated change in activity in the intervention period compared to the baseline period and the control period corelated to the changes in activity measured by the sensor.

The investigators will make a Cross-over, randomized, open label, controlled trial.

Patients will be included from the outpatient clinic, The Department of Rheumatology, Rigshospitalet - Glostrup, Region Hovedstaden, Denmark Inclusions criteria

  • Aged 18 years or older
  • Non-specific low back pain, spinal stenosis or radiculopathy.
  • Not referred for surgical evaluation.
  • Patients who scored ≥ 20 point at the Oswestry Disability Index Exclusion criteria
  • Patients with comorbidity that prevent them for participating in the study.
  • Patients who are judge by the principal investigator to not speak Danish sufficiently to enable them to comprehend the study information and app feedback.
  • Patients who already monitor their activity by a watch, on a daily basis.
  • Patients with allergy for band aid
  • Patients who are pregnant or breastfeeding

The patients are randomized to start with intervention + standard-of-care or only standard-of-care. After completion of the first period the patients will cross-over to the other period.

The patients are randomized by closed envelope. Using a randomization list from randomization.com.

Intervention period

The patients wear the SENS motion patch for 14 days and received daily updates on activity, and suggestions for improvements. During the intervention period the patients receive standard-of-care.

Control period

The patients wear the SENS motion patch for 14 days, but do not receive any feedback from the sensor. During the control period the patients receive standard-of-care.

Standard-of-care

At the outpatient clinic patients are examined by a doctor, receive a diagnosis and may undergo MRI to identify other causes for back pain. They are not offered any training program at the hospital, but they are recommended to stay active and exercise. Some may have a consultation with a physiotherapist one to two times who repeat the advice. Patients are informed that despite pain, they cannot harm their spine by work, exercise or performing daily activities, and that medical staff do not discourage any activities.

Name of the investigational device

SENS motion®, SENS-Innovation ApS

Titangade 11, 2. - 2200 Kbh. N.

Sensor

The SENS motion® system consists of:

  • The sensor 'SENS Motion Patch'
  • A smart-phone application 'SENS motion´

    • SENS motion cloud storage database, a web-based visualization of data for the healthcare team
02

Conditions studied

  • Low Back Pain
  • Radiculopathy Lumbar
  • Sciatica
03

In context

Radiculopathy

488 studies on the registry are indexed under Radiculopathy; 141 are open to participants now.

This study's enrollment of 98 is above the median of 60 across 376 interventional studies indexed under Radiculopathy.

Browse Radiculopathy studies →

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • non-specific low back pain, spinal stenosis, radiculopathy
  • moderate disability or worse (20-100 points on Oswestry Disability Index)

Exclusion criteria

Exclusion Criteria:

  • co-morbidity making the patients unable to move
  • unsufficient Danish-skills
  • patients who already monitored their activity by watch or phone on a daily basis
  • allergy to band-aid
  • pregnancy or breast-feeding
  • patients referred for back-surgical evaluation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Other
    Initial activity tracker with feedback followed by control period

    Initial activity tracker with feedback followed by control period

    Device: The SENS motion® sensor

  • Other
    Initial control period followed by activity tracker with feedback

    Initial control period followed by activity tracker with feedback

    Device: The SENS motion® sensor

Interventions

  • DeviceThe SENS motion® sensor

    The sensor is a wearable physical tracker giving investigators feedback about daily activity The SENS motion® system consists of: The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´ SENS motion cloud storage database, a web-based visualization of data for the healthcare team The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity.

    Also known as: iSpine app (InterMedCon)

06

What researchers measure

Primary outcomes

  1. Average daily activity

    The Primary outcome was defined as the difference in average (mean) daily number of minutes in activity (defined as the sum of time spent with standing, walking, cycling and exercising) in 14 days intervention period compared to 14 days control period, registered by the sensor.

    Time frame: 1 month

07

Study locations

1 site
  • COPEBACK, Rigshospitalet
    Copenhagen, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04695912
Lead sponsor
Rigshospitalet, Denmark
Responsible party
Anna Katrine Skovsgaard Itenov (senior registrar, MD, Rigshospitalet, Denmark) — Principal investigator
First posted
Jan 5, 2021
Start date
Apr 26, 2019
Primary completion
Jun 20, 2019
Completion
Jun 20, 2019
Last update
Jan 5, 2021

Study contacts

Anna katrine Itenov, MD
principal investigator · COPEBACK, Rigshospitalet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion